Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemicβ¦
ISININE049B01025
Listedβ
Quarters tracked13
Filings20 docs
Market Price
OpenHighLowPrev Close
Price unavailable
About
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine, as well as offers insulin aspart regular and biphasic drug products. Further, the company offers delivery devices for insulin, including DispoPen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
25 Aug 202625 Aug - Pursuant to Regulation 30 read with Schedule III Part A Para A of the SEBI (LODR) Regulations, 2015, we enclose herewith a copy of newspaper β¦
25 Aug 202625 Aug - Received 21 Aug 2026 customs order imposing βΉ5 crore penalty and βΉ10 crore redemption fine on Wockhardt for API misclassification.